Seaweed could become an important source of disease-fighting antioxidants, if EU scientists succeed in proving its benefits.
East Asians have long enjoyed marine vegetables, adding them to soup, as an ingredient for sushi, or making salads with a variety known as sea grapes. However, Europeans generally don’t like seaweed, despite the nutrients it absorbs from the sea.
Traditionally, those eating seaweed-based diets have shown fewer instances of obesity, diabetes, Alzheimer's disease and other disorders. Now, two EU-funded projects are trying to prove that seaweed can indeed boost health.
If the projects are successful, seaweed could be used as the basis for disease-fighting dietary supplements, even if people choose not to put it on their plates.
Europe’s share of global seaweed production stands at just 1.3 %, according to market data provided by one of the projects, SWAFAX. By contrast, China is the biggest source of seaweed, generating 64 % of the world’s supply.
However, the idea in Europe of seaweed as a health promoter is not new. At the start of the 20th century, people would head to the Atlantic coast for seaweed baths, and the practice is undergoing a resurgence as people seek to treat conditions ranging from arthritis to eczema.
SWAFAX is studying chemicals found in seaweed called polyphenols, in particular a type called phlorotannins which are found specifically in brown-coloured plants. 'Phlorotannins are unique to certain seaweeds,' said SWAFAX project leader, Ian Rowland.
SWAFAX has developed a polyphenol-based seaweed extract that can be used as a food supplement, as well as extracts based on different types of seaweed. Later this year it will have the results of tests on humans to see if the supplements have antioxidant and anti-inflammatory properties.
Alzheimer’s and Parkinson’s
‘Phlorotannins are unique to certain seaweeds.’
SWAFAX project leader, Ian Rowland
Researchers at SWAFAX suspect that seaweed could be a good source of antioxidants, which are thought to have potential in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson’s.
The idea behind SWAFAX is to give small companies the chance to commercialise anything interesting it finds, and it is working alongside three small companies: Scotland-based Hebridean Seaweed Company, which turns seaweed into animal feed; Irish firm Marigot Ltd, a food supplement firm, and Mesosystem S.L, a Spanish cosmetics company.
Another, connected EU project, HYFFI, is examining whether seaweed fibre has prebiotic properties, meaning it could aid digestive health by helping to stimulate the growth of friendly bacteria in the human gut. HYFFI observed a number of compounds that seemed to work, and now the project is running tests to see if they have any effect when introduced into people’s diets.
Seaweed is not just being used to promote health, it can also be used to make food packaging, as insulation for homes, and could even be turned into methane-based fuel.
The EU-funded project PLANTPACK, which runs until late 2014, is working out how to use seaweed combined with starch to replace oil-derived coating for paper and cardboard food containers. As well as cutting down on the use of oil in food packaging, the technique would mean that food packets degrade more easily.
SEAWEED AD, an EU-backed project which finishes at the end of August 2013, is looking at ways to ferment seaweed and produce methane for fuel, while researchers at the Fraunhofer Institute for Chemical Technology in Pfinztal, Germany, have found a way to turn seaweed into insulation for houses.
For more information on PLANTPACK, visit: http://www.plantpack.eu/
To find out more about SEAWEED AD, visit: http://cordis.europa.eu/projects/rcn/99329_en.html
An air quality study has for the first time detected nano-sized particles of air pollution in children’s urine. With a diameter of just 100 nanometers - a thousandth of the width of a human hair - these ultrafine particles are the smallest particles found in air pollution and have been linked to heart disease and respiratory conditions in previous studies.
There are many rare genetic diseases that strike perhaps only one in a million people. Often incurable, they can be profoundly debilitating and frequently life-threatening. Though each particular disease is rare, they number in the thousands – which means that together they affect about 30 million Europeans or around 7% of us. Treating these diseases is challenging and until recently, no cure was thought to be even possible for most of them. Now, hopes are rising for people living with rare genetic diseases as new treatments are being developed.
A lot of lip service is being paid to making scientific papers free to access but when it comes to action there is a lot of hypocrisy, according to Robert-Jan Smits, the EU's outgoing director-general for research, science and innovation. He has recently been appointed the EU's special envoy on open access, tasked with helping make all publicly funded research in Europe freely available by 2020.
There is a need for renewed political attention, says EU’s new special envoy.
Digital cannot replace personal experiences.
Cultural heritage destruction can be a war crime as sites form part of people's emotional landscape, says Dr van Ess.